Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items turns positive
Q1 FY2026 other non-cash items was $39.8K, compared with -$28.68K a year earlier. Trailing-twelve-month other non-cash items was $871.85K. Over 3 fiscal years it compounded at +29.6% a year.
Context
- Other non-cash items increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other non-cash items holds near $39.8K or moves back toward the trailing-twelve-month quarterly average of $217.96K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 840K USD
- Year-over-year change
- +546.2%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 840K | +546.2% |
| FY2024 | 2024-12-31 | 130K | -98.6% |
| FY2023 | 2023-12-31 | 9.1M | +2260.2% |
| FY2022 | 2022-12-31 | 385.49K | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-Cash Items vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's LTM Mar 2026 other non-cash items of $871.85K is the 4th largest of the 6 companies compared; the peer median is $399K.
- Its year-over-year change of -82.4% is the 3rd highest of 6, against a peer median of -97.0%.
- Over three fiscal years its annual growth of +29.6% compares with a peer median of -41.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.16M | +196.9% | — | 57.0% | |
| LTM Mar 2026 | $20.2M | -29378.3% | +264.5% | — | |
| LTM Mar 2026 | $2.91M | +51.9% | -58.7% | 206.0% | |
| LTM Mar 2026 | $871.85K | -82.4% | +29.6% | — | |
| LTM Mar 2026 | $848K | -175.5% | -41.4% | — | |
| LTM Mar 2026 | $399K | -97.0% | — | — | |
| Peer median (excluding TELO) | $399K | -97.0% | -41.4% | 131.5% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Depreciation & Amortization | 0 | 0 | 0 | 4.34M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 6.87M | 5.29M |
| Change in Working Capital | 18.74K | 385.49K | 113.84K | 126.47K | 594.69K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 18.74K | 0 | 114.56K | 183.63K | (50.77K) |
| Other Working Capital | 18.74K | 385.49K | (713) | (57.16K) | 645.46K |
| Other Non-Cash Items | 0 | 385.49K | 9.1M | 130K | 840K |
| Operating Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
| Capital Expenditures | (4) | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 462.39K | 3.17M | (101K) | 0 |
| Common Stock Issued | 0 | 0 | 1M | 6.83M | 9.55M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 119.4K | 7.69K | (310.38K) | (396.65K) | 155.52K |
| Financing Cash Flow | 119.4K | 470.08K | 3.86M | 6.34M | 9.71M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 1.42K | (188) | 1.26M | 6.02M |
| Free Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.